Dr. Khalil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Carson St
Jonesboro, AR 72401Phone+1 870-932-5296Fax+1 870-910-7713
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2006
UPMC Medical EducationResidency, Internal Medicine, 2000 - 2003
University of Tichreen Faculty of MedicineClass of 1994
Certifications & Licensure
AR State Medical License 2008 - 2026
TX State Medical License 2008 - 2023
FL State Medical License 2008 - 2012
TN State Medical License 2006 - 2011
MI State Medical License 2002 - 2010
PA State Medical License 2001 - 2003- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Start of enrollment: 2018 Nov 26
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsReal-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.Patricia Rich, R. Brian Mitchell, Eric Scott Schaefer, Paul R. Walker, J. Dubay
Journal for Immunotherapy of Cancer. 2021-10-01 - 60 citationsTargeting epidermal growth factor receptor: novel therapeutics in the management of cancer.Mazen Y. Khalil, Jennifer R. Grandis, Dong M Shin
Expert Review of Anticancer Therapy. 2003-06-01 - 59 citationsA phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously expos...Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Khalil, Daruka Mahadevan
British Journal of Haematology. 2017-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
